These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35078336)

  • 1. A mathematical model for phenotypic heterogeneity in breast cancer with implications for therapeutic strategies.
    Li X; Thirumalai D
    J R Soc Interface; 2022 Jan; 19(186):20210803. PubMed ID: 35078336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.
    Luque M; Sanz-Álvarez M; Santamaría A; Zazo S; Cristóbal I; de la Fuente L; Mínguez P; Eroles P; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
    Chisholm RH; Lorenzi T; Clairambault J
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer intratumour heterogeneity: current status and clinical implications.
    Joseph C; Papadaki A; Althobiti M; Alsaleem M; Aleskandarany MA; Rakha EA
    Histopathology; 2018 Nov; 73(5):717-731. PubMed ID: 29722058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
    Janiszewska M; Stein S; Metzger Filho O; Eng J; Kingston NL; Harper NW; Rye IH; Alečković M; Trinh A; Murphy KC; Marangoni E; Cristea S; Oakes B; Winer EP; Krop IE; Russnes HG; Spellman PT; Bucher E; Hu Z; Chin K; Gray JW; Michor F; Polyak K
    JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33886505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.
    Faratian D; Goltsov A; Lebedeva G; Sorokin A; Moodie S; Mullen P; Kay C; Um IH; Langdon S; Goryanin I; Harrison DJ
    Cancer Res; 2009 Aug; 69(16):6713-20. PubMed ID: 19638581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
    Montemurro F; Di Cosimo S; Arpino G
    Ann Oncol; 2013 Nov; 24(11):2715-24. PubMed ID: 23908178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.
    Van Bockstal MR; Agahozo MC; van Marion R; Atmodimedjo PN; Sleddens HFBM; Dinjens WNM; Visser LL; Lips EH; Wesseling J; van Deurzen CHM
    Mol Oncol; 2020 Apr; 14(4):671-685. PubMed ID: 32058674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer.
    Buiga P; Elson A; Tabernero L; Schwartz JM
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance.
    Zhang Y
    Pharmacol Ther; 2021 Feb; 218():107677. PubMed ID: 32898548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer.
    Jarrett AM; Bloom MJ; Godfrey W; Syed AK; Ekrut DA; Ehrlich LI; Yankeelov TE; Sorace AG
    Math Med Biol; 2019 Sep; 36(3):381-410. PubMed ID: 30239754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.
    Chen C; Baumann WT; Xing J; Xu L; Clarke R; Tyson JJ
    J R Soc Interface; 2014 Jul; 11(96):20140206. PubMed ID: 24806707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
    Ocaña A; Amir E; Pandiella A
    Breast Cancer Res; 2020 Jan; 22(1):15. PubMed ID: 32005279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.
    Keller M; Rohlf K; Glotzbach A; Leonhardt G; Lüke S; Derksen K; Demirci Ö; Göçener D; AlWahsh M; Lambert J; Lindskog C; Schmidt M; Brenner W; Baumann M; Zent E; Zischinsky ML; Hellwig B; Madjar K; Rahnenführer J; Overbeck N; Reinders J; Cadenas C; Hengstler JG; Edlund K; Marchan R
    J Exp Clin Cancer Res; 2023 Jan; 42(1):25. PubMed ID: 36670508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
    Gijsen M; King P; Perera T; Parker PJ; Harris AL; Larijani B; Kong A
    PLoS Biol; 2010 Dec; 8(12):e1000563. PubMed ID: 21203579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Share, but unequally: a plausible mechanism for emergence and maintenance of intratumour heterogeneity.
    Li X; Thirumalai D
    J R Soc Interface; 2019 Jan; 16(150):20180820. PubMed ID: 30958159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.